Journal of Molecular Histology

, Volume 45, Issue 5, pp 555–563 | Cite as

Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis

  • Libo Peng
  • Pin Tu
  • Xuan Wang
  • Shanshan Shi
  • Xiaojun Zhou
  • Jiandong Wang
Original Paper


Erythropoietin-producing hepatocyte (Eph) receptor family constitutes the largest family of tyrosine kinase receptors in the human genome. Loss of EphB6, a kinase-deficient receptor, correlated with a negative outcome in several carcinomas. This study aimed to investigate the expression of EphB6 protein and mRNA levels in colorectal cancers (CRCs) and possible correlations with clinicopathological variables and prognosis. To assess protein expression level, 124 CRCs and 57 colorectal adenomas samples were examined by immunostaining, the mRNA level of 43 paired CRC and the adjacent normal tissues were detected by using SYBR Green real-time PCR method. Decreased expression of EphB6 protein was found in CRC as compared with adenoma and normal tissues (χ2 = 10.146, P = 0.001 and χ2 = 45.333, P < 0.001, respectively). Low EphB6 mRNA expression was detected in 83.8 % of cancers with negative or low EphB6 protein expression. The loss of EphB6 protein in CRC was positively associated with poorly differentiation (P < 0.001), lymph node metastasis (P = 0.006), Dukes stage (P = 0.002) and depth of invasion (P = 0.016). The patients with lymph node metastasis had a worse prognosis independently of gender, age, tumor site, stage and differentiation (RR = 0.404, CI 0.267–0.213, P < 0.001). Low levels of EphB6 protein expression are associated with a shorter mean duration of survival in colorectal cancer. Our results demonstrated that EphB6 may represent a novel, useful tissue biomarker for the prediction of survival rate in CRC.


EphB6 Colorectal cancer Prognosis 



This work was supported in part by the National Natural Science Foundation of China (81371611, 81171391, 81372743) and the National Basic Research Priorities Program 973 Project (2014CB744504) from the Ministry of Science and Technology of China. We thank Prof. Fred Biddle for his help in modification of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H (2010) Distinct genetic alterations in colorectal cancer. PLoS One 5:e8879. doi: 10.1371/journal.pone.0008879 PubMedCentralPubMedCrossRefGoogle Scholar
  2. Balakrishnan A et al (2007) Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67:3545–3550. doi: 10.1158/0008-5472.can-07-0065 PubMedCrossRefGoogle Scholar
  3. Batlle E et al (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435:1126–1130. doi: 10.1038/nature03626 PubMedCrossRefGoogle Scholar
  4. Brantley-Sieders DM (2012) Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev Biol 23:102–108. doi: 10.1016/j.semcdb.2011.10.014 PubMedCentralPubMedCrossRefGoogle Scholar
  5. Compton CC, Greene FL (2004) The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54:295–308PubMedCrossRefGoogle Scholar
  6. Coulthard MG et al (2002) The role of the Eph-ephrin signalling system in the regulation of developmental patterning. Int J Dev Biol 46:375–384PubMedGoogle Scholar
  7. Ding L et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075. doi: 10.1038/nature07423 PubMedCentralPubMedCrossRefGoogle Scholar
  8. Elias D et al (2014) Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg. doi: 10.1097/SLA.0000000000000582 Google Scholar
  9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi: 10.1002/ijc.25516 PubMedCrossRefGoogle Scholar
  10. Fox BP, Kandpal RP (2006) Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem Biophys Res Commun 340:268–276. doi: 10.1016/j.bbrc.2005.11.174 PubMedCrossRefGoogle Scholar
  11. Greenman C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158. doi: 10.1038/nature05610 PubMedCentralPubMedCrossRefGoogle Scholar
  12. Guo DL et al (2006) Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27:454–464. doi: 10.1093/carcin/bgi259 PubMedCrossRefGoogle Scholar
  13. Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M, Vogt T (2003) Loss of EphB6 expression in metastatic melanoma. Int J Oncol 23:1553–1559PubMedGoogle Scholar
  14. Hafner C et al (2004) Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490–499. doi: 10.1373/clinchem.2003.026849 PubMedCrossRefGoogle Scholar
  15. Herath NI, Boyd AW (2010) The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer 126:2003–2011. doi: 10.1002/ijc.25147 PubMedGoogle Scholar
  16. Herath NI, Doecke J, Spanevello MD, Leggett BA, Boyd AW (2009) Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer 100:1095–1102. doi: 10.1038/sj.bjc.6604970 PubMedCentralPubMedCrossRefGoogle Scholar
  17. Himanen JP (2012) Ectodomain structures of Eph receptors. Semin Cell Dev Biol 23:35–42. doi: 10.1016/j.semcdb.2011.10.025 PubMedCrossRefGoogle Scholar
  18. Kataoka H et al (2004) Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 95:136–141PubMedCrossRefGoogle Scholar
  19. Kosinski C et al (2007) Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 104:15418–15423. doi: 10.1073/pnas.0707210104 PubMedCentralPubMedCrossRefGoogle Scholar
  20. Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–486. doi: 10.1038/nrm856 PubMedCrossRefGoogle Scholar
  21. Lisabeth EM, Falivelli G, Pasquale EB (2013) Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol 5. doi: 10.1101/cshperspect.a009159
  22. Menzel P, Valencia F, Godement P, Dodelet VC, Pasquale EB (2001) Ephrin-A6, a new ligand for EphA receptors in the developing visual system. Dev Biol 230:74–88. doi: 10.1006/dbio.2000.0109 PubMedCrossRefGoogle Scholar
  23. Merlos-Suarez A, Batlle E (2008) Eph-ephrin signalling in adult tissues and cancer. Curr Opin Cell Biol 20:194–200. doi: 10.1016/ PubMedCrossRefGoogle Scholar
  24. Migheli F, Migliore L (2012) Epigenetics of colorectal cancer. Clin Genet 81:312–318. doi: 10.1111/j.1399-0004.2011.01829.x PubMedCrossRefGoogle Scholar
  25. Nakamura PA, Cramer KS (2013) EphB2 signaling regulates lesion-induced axon sprouting but not critical period length in the postnatal auditory brainstem. Neural Dev 8:2. doi: 10.1186/1749-8104-8-2 PubMedCentralPubMedCrossRefGoogle Scholar
  26. Nikolov DB, Xu K, Himanen JP (2013) Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim Biophys Acta 1834:2160–2165. doi: 10.1016/j.bbapap.2013.04.020 PubMedCrossRefGoogle Scholar
  27. Saika K, Sobue T (2013) Cancer statistics in the world. Gan To Kagaku Ryoho 40:2475–2480PubMedGoogle Scholar
  28. Senior PV, Zhang BX, Chan ST (2010) Loss of cell-surface receptor EphB2 is important for the growth, migration, and invasiveness of a colon cancer cell line. Int J Colorectal Dis 25:687–694. doi: 10.1007/s00384-010-0916-7 PubMedCrossRefGoogle Scholar
  29. Sheng Z et al (2008) EphB1 is underexpressed in poorly differentiated colorectal cancers. Pathobiology 75:274–280. doi: 10.1159/000151707 PubMedCrossRefGoogle Scholar
  30. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489–499. doi: 10.1038/nrc2645 PubMedCrossRefGoogle Scholar
  31. Wang J et al (2005) Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24:5637–5647. doi: 10.1038/sj.onc.1208720 PubMedCrossRefGoogle Scholar
  32. Xi HQ, Wu XS, Wei B, Chen L (2012) Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med 16:2894–2909. doi: 10.1111/j.1582-4934.2012.01612.x PubMedCrossRefGoogle Scholar
  33. Yu J et al (2010) The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res 16:2275–2283. doi: 10.1158/1078-0432.ccr-09-2000 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Libo Peng
    • 1
  • Pin Tu
    • 1
  • Xuan Wang
    • 1
  • Shanshan Shi
    • 1
  • Xiaojun Zhou
    • 1
  • Jiandong Wang
    • 1
  1. 1.Department of Pathology, Jinling HospitalSouthern Medical UniversityNanjingChina

Personalised recommendations